Literature DB >> 31974473

Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer.

Sarah Ouahoud1, Philip W Voorneveld1, Lukas J A C Hawinkels1, James C H Hardwick2, Lennart R A van der Burg1, Eveline S M de Jonge-Muller1, Mark J A Schoonderwoerd1, Madelon Paauwe1, Thijs de Vos1, Sophie de Wit1, Gabi W van Pelt3, Wilma E Mesker3.   

Abstract

Patients with the mesenchymal subtype colorectal cancer (CRC) have a poor prognosis, in particular patients with stroma-rich tumors and aberrant SMAD4 expression. We hypothesized that interactions between SMAD4-deficient CRC cells and cancer-associated fibroblasts provide a biological explanation. In transwell invasion assays, fibroblasts increased the invasive capacity of SMAD4-deficient HT29 CRC cells, but not isogenic SMAD4-proficient HT29 cells. A TGF-β/BMP-specific array showed BMP2 upregulation by fibroblasts upon stimulation with conditioned medium from SMAD4-deficient CRC cells, while also stimulating their invasion. In a mouse model for experimental liver metastasis, the co-injection of fibroblasts increased metastasis formation of SMAD4-deficient CRC cells (p = 0.02) but not that of SMAD4-proficient CRC cells. Significantly less metastases were seen in mice co-injected with BMP2 knocked-down fibroblasts. Fibroblast BMP2 expression seemed to be regulated by TRAIL, a factor overexpressed in SMAD4-deficient CRC cells. In a cohort of 146 stage III CRC patients, we showed that patients with a combination of high stromal BMP2 expression and the loss of tumor SMAD4 expression had a significantly poorer overall survival (HR 2.88, p = 0.04). Our results suggest the existence of a reciprocal loop in which TRAIL from SMAD4-deficient CRC cells induces BMP2 in fibroblasts, which enhances CRC invasiveness and metastasis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31974473     DOI: 10.1038/s41388-020-1157-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

2.  Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation.

Authors:  Zhen Lv; Xianlei Cai; Xiaoyu Weng; Heng Xiao; Chengli Du; Jun Cheng; Lin Zhou; Haiyang Xie; Ke Sun; Jian Wu; Shusen Zheng
Journal:  Surgery       Date:  2015-04-15       Impact factor: 3.982

3.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

Authors:  Alexandre Calon; Enza Lonardo; Antonio Berenguer-Llergo; Elisa Espinet; Xavier Hernando-Momblona; Mar Iglesias; Marta Sevillano; Sergio Palomo-Ponce; Daniele V F Tauriello; Daniel Byrom; Carme Cortina; Clara Morral; Carles Barceló; Sebastien Tosi; Antoni Riera; Camille Stephan-Otto Attolini; David Rossell; Elena Sancho; Eduard Batlle
Journal:  Nat Genet       Date:  2015-02-23       Impact factor: 38.330

4.  Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma.

Authors:  Jing Liu; Juan Liu; Jinsong Li; Yingling Chen; Xiaoling Guan; Xiaojuan Wu; Chunyan Hao; Yanlin Sun; Yan Wang; Xiao Wang
Journal:  Gynecol Oncol       Date:  2013-11-09       Impact factor: 5.482

5.  Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma.

Authors:  Kai Wang; Wei Ma; Jianbo Wang; Liang Yu; Xiaomei Zhang; Zhenbo Wang; Bingxu Tan; Nana Wang; Bing Bai; Shengsi Yang; Houqiang Liu; Shengjie Zhu; Yufeng Cheng
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

6.  Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).

Authors:  T J A Dekker; C J H van de Velde; G W van Pelt; J R Kroep; J-P Julien; V T H B M Smit; R A E M Tollenaar; W E Mesker
Journal:  Breast Cancer Res Treat       Date:  2013-05-25       Impact factor: 4.872

7.  The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Authors:  A Huijbers; R A E M Tollenaar; G W v Pelt; E C M Zeestraten; S Dutton; C C McConkey; E Domingo; V T H B M Smit; R Midgley; B F Warren; E C Johnstone; D J Kerr; W E Mesker
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

8.  Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.

Authors:  Wilma E Mesker; Gerrit-Jan Liefers; Jan M C Junggeburt; Gabi W van Pelt; Paola Alberici; Peter J K Kuppen; Noel F Miranda; Karin A M van Leeuwen; Hans Morreau; Karoly Szuhai; Rob A E M Tollenaar; Hans J Tanke
Journal:  Cell Oncol       Date:  2009       Impact factor: 6.730

9.  The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.

Authors:  Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  10 in total

1.  CCL7 and TGF-β secreted by MSCs play opposite roles in regulating CRC metastasis in a KLF5/CXCL5-dependent manner.

Authors:  Zhuoqing Xu; Han Gao; Yuchen Zhang; Wenqing Feng; Yiming Miao; Zifeng Xu; Wenchang Li; Fangqian Chen; Zeping Lv; Jianting Huo; Wangyi Liu; Xiaohui Shen; Yaping Zong; Jingkun Zhao; Aiguo Lu
Journal:  Mol Ther       Date:  2022-03-10       Impact factor: 12.910

Review 2.  Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.

Authors:  Shogo Ehata; Kohei Miyazono
Journal:  Front Cell Dev Biol       Date:  2022-05-25

3.  Development and Validation of an Autophagy-Stroma-Based Microenvironment Gene Signature for Risk Stratification in Colorectal Cancer.

Authors:  Lin Chen; Kunzi Zhang; Jian Sun; Jingtong Tang; Jianping Zhou
Journal:  Onco Targets Ther       Date:  2021-05-31       Impact factor: 4.147

Review 4.  Fibroblast Subsets in Intestinal Homeostasis, Carcinogenesis, Tumor Progression, and Metastasis.

Authors:  Hao Dang; Tom J Harryvan; Lukas J A C Hawinkels
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 5.  Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.

Authors:  You-Take Oh; Shi-Yong Sun
Journal:  Biomolecules       Date:  2021-03-26

Review 6.  p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance.

Authors:  Leonel Cardozo de Menezes E Souza; Anderson Faletti; Carla Pires Veríssimo; Mariana Paranhos Stelling; Helena Lobo Borges
Journal:  Membranes (Basel)       Date:  2022-02-09

7.  Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models.

Authors:  Shulin Li; Sanne J M Hoefnagel; Matthew Read; Sybren Meijer; Mark I van Berge Henegouwen; Suzanne S Gisbertz; Elena Bonora; David S H Liu; Wayne A Phillips; Silvia Calpe; Ana C P Correia; Maria D C Sancho-Serra; Sandro Mattioli; Kausilia K Krishnadath
Journal:  Cell Oncol (Dordr)       Date:  2022-07-28       Impact factor: 7.051

8.  Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.

Authors:  Miyuki Hiratsuka; Takahiro Hasebe; Toshiaki Saeki; Yuki Ichinose; Ayaka Sakakibara; Akihiro Fujimoto; Noriko Wakui; Satomi Shibasaki; Masataka Hirasaki; Masanori Yasuda; Akemi Nukui; Hiroko Shimada; Hideki Yokogawa; Kazuo Matsuura; Takashi Hojo; Akihiko Osaki
Journal:  Virchows Arch       Date:  2022-06-13       Impact factor: 4.535

Review 9.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 10.  Tumour heterogeneity and evolutionary dynamics in colorectal cancer.

Authors:  Dedrick Kok Hong Chan; Simon James Alexander Buczacki
Journal:  Oncogenesis       Date:  2021-07-16       Impact factor: 7.485

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.